These implied that fatty acids metabolism in ccRCC was associated with JAK-STAT3 signaling and the risk score levels could reflect the therapeutic effect of ccRCC patients treated with anti-PD-1/PD-L1. Here, STAT3 is linked to nonpapillary renal cell carcinoma.